FY2025 EPS Estimates for Globus Medical Raised by Analyst

Globus Medical, Inc. (NYSE:GMED) – Equities researchers at Zacks Research lifted their FY2025 earnings per share estimates for shares of Globus Medical in a report released on Friday, January 30th. Zacks Research analyst Team now forecasts that the medical device company will post earnings of $3.77 per share for the year, up from their previous forecast of $3.76. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Globus Medical’s current full-year earnings is $3.44 per share. Zacks Research also issued estimates for Globus Medical’s Q4 2025 earnings at $1.05 EPS, Q3 2026 earnings at $0.99 EPS and Q4 2027 earnings at $1.14 EPS.

Globus Medical (NYSE:GMED) last released its quarterly earnings data on Thursday, November 6th. The medical device company reported $1.18 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.39. The business had revenue of $769.05 million during the quarter, compared to analyst estimates of $734.58 million. Globus Medical had a net margin of 15.30% and a return on equity of 11.52%. Globus Medical’s revenue was up 22.9% compared to the same quarter last year. During the same period last year, the business earned $0.83 EPS. Globus Medical has set its FY 2025 guidance at 3.750-3.85 EPS.

Other analysts have also issued research reports about the company. Wall Street Zen raised Globus Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 3rd. Barclays lifted their price objective on Globus Medical from $106.00 to $114.00 and gave the stock an “overweight” rating in a report on Monday, November 10th. Piper Sandler reissued an “overweight” rating and issued a $115.00 target price (up previously from $90.00) on shares of Globus Medical in a research report on Thursday, January 8th. Canaccord Genuity Group raised their price target on shares of Globus Medical from $105.00 to $112.00 and gave the company a “buy” rating in a report on Friday, January 9th. Finally, Wells Fargo & Company lifted their price target on shares of Globus Medical from $66.00 to $79.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $100.18.

Globus Medical Stock Down 2.6%

Shares of NYSE GMED opened at $87.39 on Monday. The firm has a market cap of $11.70 billion, a P/E ratio of 28.19, a PEG ratio of 1.38 and a beta of 1.06. Globus Medical has a twelve month low of $51.79 and a twelve month high of $101.40. The company has a 50 day moving average of $90.04 and a 200 day moving average of $72.11.

Insiders Place Their Bets

In other news, SVP Kelly Huller sold 7,500 shares of the company’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $90.00, for a total value of $675,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David D. Davidar sold 25,000 shares of Globus Medical stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $86.00, for a total value of $2,150,000.00. Following the transaction, the director owned 516,275 shares in the company, valued at $44,399,650. This trade represents a 4.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 91,636 shares of company stock valued at $7,984,583. 18.54% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC increased its holdings in Globus Medical by 45.9% in the 1st quarter. AQR Capital Management LLC now owns 22,510 shares of the medical device company’s stock worth $1,622,000 after acquiring an additional 7,086 shares in the last quarter. Integrated Wealth Concepts LLC boosted its position in shares of Globus Medical by 33.0% in the first quarter. Integrated Wealth Concepts LLC now owns 4,375 shares of the medical device company’s stock worth $320,000 after purchasing an additional 1,085 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Globus Medical by 38.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,649 shares of the medical device company’s stock worth $2,228,000 after purchasing an additional 8,540 shares in the last quarter. Jones Financial Companies Lllp increased its stake in shares of Globus Medical by 237.3% in the first quarter. Jones Financial Companies Lllp now owns 850 shares of the medical device company’s stock worth $62,000 after purchasing an additional 598 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Globus Medical by 8.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,527 shares of the medical device company’s stock valued at $25,439,000 after purchasing an additional 28,027 shares during the period. Institutional investors own 95.16% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.